• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes care >Clinical significance of urinary liver-type Fatty Acid-binding protein in diabetic nephropathy of type 2 diabetic patients.
【24h】

Clinical significance of urinary liver-type Fatty Acid-binding protein in diabetic nephropathy of type 2 diabetic patients.

机译：尿肝型脂肪酸结合蛋白在2型糖尿病患者肾病中的临床意义。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE Urinary liver-type fatty acid-binding protein (L-FABP) is a promising indicator of tubular but not glomerular damage. The aim of this study was to evaluate the clinical usefulness of urinary L-FABP as a prognostic biomarker in impaired diabetic nephropathy in type 2 diabetes. RESEARCH DESIGN AND METHODS This investigation involved a cross-sectional and longitudinal analysis of the relationship between urinary L-FABP levels and progressive nephropathy. Urinary L-FABP was measured with enzyme-linked immunosorbent assay. In the cross-sectional analysis, the association of urinary L-FABP, with the severity of diabetic nephropathy, was investigated in 140 patients with type 2 diabetes and in 412 healthy control subjects. Of the patients in the former study, 104 have been followed for 4 years. The progression of diabetic nephropathy was defined as progressive albuminuria, end-stage renal disease, or induction of hemodialysis. RESULTS Urinary L-FABP levels were progressively increased in subjects with normo-, micro-, or macroalbuminuria and further increased in patients with end-stage renal disease. In the longitudinal analysis, high urinary L-FABP levels were associated with the increase in albuminuria, progression to end-stage renal disease, or induction of hemodialysis. This was particularly demonstrated in the subgroup of patients without renal dysfunction (n = 59), where high urinary L-FABP levels were associated with the progression of diabetic nephropathy. CONCLUSIONS Urinary L-FABP accurately reflected the severity of diabetic nephropathy in type 2 diabetes, and its level was high in the patients with normoalbuminuria. Moreover, higher urinary L-FABP was a risk factor for progression of diabetic nephropathy.
机译：目的尿肝型脂肪酸结合蛋白（L-FABP）是肾小管但不是肾小球损害的有希望的指标。这项研究的目的是评估尿L-FABP作为2型糖尿病糖尿病肾病受损的预后生物标志物的临床实用性。研究设计和方法这项研究涉及横断面和纵向分析尿L-FABP水平与进行性肾病之间的关系。用酶联免疫吸附测定法测定尿液中的L-FABP。在横断面分析中，调查了140例2型糖尿病患者和412例健康对照者的尿L-FABP与糖尿病肾病严重程度的关系。在先前的研究中，有104位患者被随访了4年。糖尿病性肾病的进展被定义为进行性白蛋白尿，终末期肾脏疾病或引起血液透析。结果正常白蛋白尿，微量白蛋白尿或大型白蛋白尿患者的尿液L-FABP水平逐渐升高，而终末期肾脏疾病患者的尿液中L-FABP水平逐渐升高。在纵向分析中，高尿L-FABP水平与蛋白尿增加，进展为终末期肾脏疾病或诱导血液透析有关。这在没有肾功能不全的患者亚组中特别得到证实（n = 59），其中高尿L-FABP水平与糖尿病肾病的进展有关。结论尿L-FABP可以准确反映2型糖尿病的糖尿病肾病的严重程度，在正常白蛋白尿患者中其水平较高。此外，较高的尿液L-FABP是糖尿病肾病进展的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号